Alector, Inc. (ALEC) Dividend History

Alector, Inc. (ALEC) is a biotechnology company focused on discovering and developing immuno-neurology medicines to treat neurodegenerative diseases and cancer. The company's platform leverages insights into the immune system's role in neurodegeneration, aiming to develop targeted therapies for conditions such as Alzheimer’s disease, ALS, and other neuroinflammatory disorders.

131 Oyster Point Blvd., Suite 600, South San Francisco, CA, 94080
Phone: 415-231-5660
Website: https://www.alector.com

Dividend History

Alector, Inc. currently does not pay dividends

Company News

Alector to Participate in Upcoming Healthcare Conferences

Alector, a late-stage clinical biotechnology company, announced that it will participate in upcoming investor conferences, where it will present its therapies for neurodegenerative diseases.

GlobeNewswire Inc.
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Alector, a late-stage clinical biotechnology company, provided an update on its pipeline, including the anticipated topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation, and the ongoing PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease. The company also highlighted its preclinical and research pipeline, including programs leveraging its Alector Brain Carrier technology.

GlobeNewswire Inc.
Alector to Participate in Upcoming Healthcare Conferences

Alector, a clinical-stage biotechnology company, announced that it will participate in several upcoming investor conferences, including the Morgan Stanley 22nd Annual Global Healthcare Conference, the H.C. Wainwright 26th Annual Global Investment Conference, and the 2024 Cantor Global Healthcare Conference.

GlobeNewswire Inc.
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of its TREM2 agonist AL002 in early Alzheimer's disease. The trial enrolled a representative population, allowing for testing of the novel TREM2 agonist.

GlobeNewswire Inc.

Featured Companies: ABBV
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Investment Research

Featured Companies: PRTA

Dividend data last updated 06/07/2025 19:58:57 UTC